Ask AI
ProCE Banner Activity

Immunotherapy in Resectable Early-Stage NSCLC

Slideset

Recent data, evolving guidelines, and real-world clinical experience have raised ongoing questions about how to personalize perioperative treatment regimens for patients with resectable early-stage NSCLC. In this downloadable slideset, learners will examine the latest evidence and expert recommendations for integrating immunotherapy into multimodal treatment and consider how it applies to treatment selection and multidisciplinary management of immunotherapy-eligible patients with resectable early-stage NSCLC.

Released: July 20, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education, in partnership with Smart Patients.

ProCE Banner

Supporters

Supported by an educational grant from Merck Sharp & Dohme LLC.

Merck Sharp & Dohme, LLC

Partners

Smart Patients

ProCE Banner

Target Audience

This activity is intended for medical oncologists, surgical oncologists, surgeons, nurse practitioners, physician associates, nurses, pharmacists, and other healthcare professionals involved in the multidisciplinary care of patients with resectable early-stage NSCLC in community and academic practices.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify patients with resectable early-stage NSCLC who are eligible for immunotherapy through evidence-based molecular testing

  • Design a personalized multimodal treatment plan for immunotherapy-eligible patients with resectable early-stage NSCLC based on the latest data and expert recommendations

  • Counsel all eligible patients on the risk–benefit profile, goals, and administration options for neo/adjuvant immunotherapy-based treatment using evidence-based resources

  • Manage immune-related adverse events concordant with the latest guidelines to optimize the quality of life and clinical outcomes for each patient with early-stage resectable NSCLC